The Innate Immune Responses, Adjuvants and Delivery Systems

Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines

Volumn , Issue , 2009, Pages 113-127

  Moghimi, S Moein ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adjuvants as immunomodulators and antigen delivery systems; Antigen capture; Antigen delivery pathway; DCs, expressing complement receptors (CRs); DCs, unique antigen presenting cells; Improved understanding of adjuvant mechanisms of action in different species; Innate immune responses, adjuvants and delivery systems; Signalling receptors and adjuvant role

Indexed keywords

EID: 84866035848     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470688397.ch6     Document Type: Chapter

References (88)

1. Holmgren, J. and Czerkinsky, C. (2005) Mucosal immunity and vaccines. Nat. Med., 11, S45-S53.
2. Ulmer, J.B., Valley, U. and Rappuoli, R. (2006) Vaccine manufacturing: challenges and solutions . Nat. Biotechnol., 24, 1377-1383.
3. Steinman, R.M. and Banchereau, J. (2007) Taking dendritic cells into medicine. Nature, 449, 419-426.
4. Hoebe, K., Janssen, E. and Beutler, B. (2004) The interface between innate and adaptive immunity. Nat. Immunol., 5, 971-974.
5. Pashine, A., Valiante, N.M. and Ulmer, J.B. (2005) Targeting the innate immune response with improved vaccine adjuvants, Nat. Med., 11, S63-S68.
6. Guy, B. (2007) The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol., 5, 505-517.
7. Linblad, E.B. (2004) Aluminium adjuvants-in retrospect and prospect. Vaccine, 22, 3658-3668.
8. Linblad, E.B. (2004) Aluminium compounds for use in vaccines. Immunol. Cell Biol., 82, 497-505.
9. Combadiere, B. and Mahe, B. (2008) Particle-based vaccines for transcutaneous vaccination. Comp. Immunol. Microbiol. Infect. Dis., 31, 293-315.
10. Gupta, R.K. and Siber, G.R. (1995) Adjuvants for human vaccines-current status, problems and future prospects. Vaccine, 13, 1263-1276.
11. Morein, B., Sundquist, B., Hoglund, S. et al. (1984) Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature, 308, 457-460.
12. Banchereau, J., Briere, F., Caux, C. et al. (2000) Immunobiology of dendritic cells. Ann. Rev. Immunol., 18, 767-811.
13. Randolph, G.J., Angeli, V. and Swartz, M.A. (2005) Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol., 5, 617-628.
14. Steinman, R.M., Hawiger, D. and Nussenzweig, M.C. (2003) Tolerogenic dendritic cells. Ann. Rev. Immunol., 21, 685-711.
15. Lutz, M.B. and Schuler, G. (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trend Immunol., 23, 445-449.
16. Ingulli, E., Ulman, D.R., Lucido, M.M. and Jenkins, M.K. (2002) In situ analysis reveals physical interactions between CD11b + dendritic cells and antigen-specific CD4 T cells after subcutaneous injection of antigen. J. Immunol., 169, 2247-2252.
17. Sixt, M., Kanazawa, N., Selg, M. et al. (2005) The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in T cell area of the lymph node. Immunity, 22, 19-29.
18. Nolte, M.A., Belien, J.A., Schadee-Eestermans, I. et al. (2003) A conduit system distributes chemokines and small blood-borne molecules through splenic white pulp. J. Exp. Med., 198, 505-512.
19. Reddy, S.T., van der Vlies, A.J., Simenoi, E. et al. (2007) Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol., 25, 1159-1164.
20. Moghimi, S.M., Hawley, A.E., Christy, N.M. et al. (1994) Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett., 344, 25-30.
21. Moghimi, S.M. (2003) Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: the effect of the ethylene oxide chain configuration. FEBS Lett., 540, 241-244.
22. Knight, S.C. (2008) Specialized perinodal fat fuels and fashions immunity. Immunity, 28, 135-138.
23. Tilg, H. and Moschen, A.R. (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol., 6, 772-783.
24. Thurnher, M. (2007) Lipids in dendritic cell biology: messengers, effectors, and antigens. J. Leukoc. Biol., 81, 154-160.
25. Pond, C.M. (2003) Paracrine relationships between adipose and lymphoid tissues: implications for the mechanism of HIV-associated adipose redistribution syndrome. Trend Immunol., 24, 13-18.
26. Sallusto, F., Cella, M., Danieli, C. and Lanzavecchia, A. (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med., 182, 389-400.
27. Reis e Sousa, C., Stahl, P.D. and Austyn, J.M. (1993) Phagocytosis of antigens by Langerhans cells in vitro. J. Exp. Med., 178, 509-519.
28. Jing, W., Swiggard, W.J., Heufler, C. et al. (1995) The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature, 375, 151-155.
29. Engering, A.J., Cella, M., Fluitsma, D. et al. (1997) The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol., 27, 2417-2425.
30. Tan, M.C., Mommaas, A.M., Drijfhout, J.W. et al. (1997) Mannose receptor-mediated uptake of antigens strongly enhances HLC class II-restricted antigen presentation by cultured dendritic cells. Eur. J. Immunol., 27, 2426-2435.
31. Geijtenbeek, T.B., Torensma, R., van Vliet, S.J. et al. (2000) Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune response. Cell, 100, 575-585.
32. Delneste, Y., Magistrelli, G., Gauchat, J.F. et al. (2002) Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity, 17, 353-362.
33. Valladeau, J., Duvert-Frances, V., Pin, J.J. et al. (1999) The monoclonal antibody DCGM4 recognizes langerin, a protein specific of Langerhans cells, and is rapidly internalized from the cell surface. Eur. J. Immunol., 29, 2695-2704.
34. Dudziak, D., Kamphorst, A.O., Heidkamp, G.F. et al. (2007) Differential antigen processing by dendritic cell subsets in vivo. Science, 315, 107-111.
35. Ariizumi, K., Shen, G-L., Shikano, S. et al. (2000) Cloning of a second dendritic cell-associated C-type lectin (Dectin-2) and its alternatively spliced isoforms. J. Biol. Chem., 275, 11957-11963.
36. Mommaas, A.M., Mulder, A.A., Jordens, R. et al. (1999) Human epidermal Langerhans cells lack functional mannose receptors and a fully developed endosomal/lysosomal compartment for loading of HLA class II molecules. Eur. J. Immunol., 29, 571-580.
37. Kissenpfennig, A., Henri, S., Dubois, B. et al. (2005) Dynamics and function of Langerhans cells in vivo. Immunity, 22, 643-654.
38. Bates, E.E., Dieu, M-C., Ravel, O. et al. (1998) CD40L activation of dendritic cells down-regulate DORA, a novel member of immunoglobulin superfamily. Mol. Immunol., 35, 513-524.
39. Cella, M., Dohring, C., Samaridis, J. et al. (1997) A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J. Exp. Med., 185, 1743-1751.
40. Fanger, N.A., Wardwell, K., Shen, L. et al. (1996) Type I (CD64) and type II (CD32) Fc γ receptor-mediated phagocytosis by human blood dendritic cells. J. Immunol., 157, 541-548.
41. Rozis, G., de Silva, S., Benlahrech, A. et al. (2005) Langerhans cells are more efficiently transduced than dermal dendritic cells by adenovirus vectors expressing either group C or group B fibre protein: implications for mucosal vaccines. Eur. J. Immunol., 35, 2617-2626.
42. Behrens, E.M., Sriram, U., Shivers, D.K. et al. (2007) Complement receptor e ligation of dendritic cells suppresses their stimulatory capacity. J. Immunol., 178, 6268-6279.
43. Zabel, M.D. and Weis, J.H. (2001) Cell-specific regulation of the CD21 gene. Int. Immunopharmacol., 1, 483-493.
44. Dempsey, P.W., Allison, M.E., Akkaraju, S. et al. (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science, 271, 348-350.
45. Csomor, E., Bajtaya, Z., Sandora, N. et al. (2007) Complement protein C1q induces maturation of human dendritic cells. Mol. Immunol., 44, 3389-3397.
46. O'Hagan, D.T., Singh, M. and Ulmer, J.B. (2004) Microparticles for the delivery of DNA vaccines. Immunol. Rev., 199, 191-200.
47. O'Hagan, D.T. and Rappuoli, R. (2004) Novel approaches to vaccine delivery. Pharm. Res., 21, 1519-1530.
48. Pantarotto, D., Partidos, C.D., Hoebeke, J. et al. (2003) Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem. Biol., 10, 991-996.
49. Akagi, T., Wang, X., Uto, T. et al. (2007) Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials, 28, 3427-3436.
50. Jia, L., Kovacs, J.R., Zheng, Y. et al. (2008) Expansion of Foxp3-expressing regulatory T cells in vitro by dendritic cells modified with polymeric particles carrying a plasmid encoding interleukin-10. Biomaterials, 29, 1250-1261.
51. Perrie, Y., Mohammed, A.R., Kiby, D.J. et al. (2008) Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharmaceut., 364, 272-280.
52. Simecka, J.W. (1998) Mucosal immunity of gastrointestinal tract and oral tolerance. Adv. Drug Deliv. Rev., 34, 235-259.
53. Lavelle, E.C. (2001) Targeted delivery of drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst., 18, 341-386.
54. Tran, K.K. and Shon, H. (2009) The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells. Biomaterials. 30, 1356-1362.
55. Drummond, D.C., Zignani, M. and Leroux, J.C. (2000) Current status of pH-sensitive liposomes in drug delivery. Prog. Lipid. Res., 39, 409-460.
56. Heffernan, M.J., Kasturi, S.P., Yang, S.C. et al. (2009) The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). Biomaterials, 30, 910-918.
57. Boudier, A., Aubert-Pouessel, A., Louis-Plence, P. et al. (2009) The control of dendritic cell maturation by pH-sensitive polyion complex micelles. Biomaterials, 30, 233-241.
58. Beauregard, K.E., Lee, K.D., Collier, R.J. and Swanson, J.A. (1997) pH-dependent perforation of macrophage phagosomes by Listeriolysin O from Listeria monocytogenes. J. Exp. Med., 186, 1159-1163.
59. Lee, K.D., Oh, Y.K., Portnoy, D.A. and Swanson, J.A. (1996) Delivery of macromolecules into cytosol using liposome containing hemolysin from Listeria monocytogenes. J. Biol. Chem., 271, 7249-7252.
60. Salvador-Morales, C., Flahaut, E., Sim, E. et al. (2006) Complement activation and protein adsorption by carbon nanotubes. Mol. Immunol., 43, 193-201.
61. Hamad, I., Hunter, A.C., Rutt, K.J. et al. (2008) Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol. Immunol., 45, 3797-3803.
62. Moghimi, S.M. and Hamad, I. (2008) Liposome-mediated triggering of complement cascade. J. Liposome Res., 18, 195-209.
63. Hunter, R.L., McNicholl, J. and Lal, A.A. (1994) Mechanisms of action of nonionic block copolymer adjuvants. AIDS Res. Hum. Retroviruses, 10, S95-S98.
64. Moghimi, S.M., Hunter, A.C., Dadswell, C.M. et al. (2004) Causative factors behind poloxamer 188 (Pluronic F68, Flocor ™)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim. Biophys. Acta, 1689, 103-113.
65. Moghimi, S.M. and Szebeni, J. (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 42, 463-478.
66. Gaymalov, Z.Z., Yang, Z., Pisarev, V.M. et al. (2009) The effect of nonionic block copolymer pluronic P85 on gene expression in mouse and antigen-presenting cells. Biomaterials. 30, 1232-1245.
67. Malmgaard, L. (2005) Dendritic cells, toll-like receptors, and T-cell responses: lessons from viral infections in vivo. Viral Immunol., 18, 584-594.
68. Barton, G.M. and Medzhitov, R. (2002) Toll-like receptors and their ligands. Curr. Topic Microbiol. Immunol., 270, 81-92.
69. Gordon, S. (2002) Pattern recognition receptors: doubling up for the innate immune response. Cell, 111, 927-930.
70. Ito, T., Amakawa, R., Kaisho, T. et al. (2002) Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med., 195, 1507-1512.
71. Jarrossay, D., Napolitani, G., Colonna, M. et al. (2001) Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol., 31, 3388-3393.
72. Uronen-Hansson, H., Allen, J., Osman, M. et al. (2004) Toll-like receptor 2 (TLR2) and TLR4 are present inside human dendritic cells, associated with microtubules and glogi apparatus but are not detectable on the cell surface: integrity of microtubules is required for interleukin-12 production in response to internalized bacteria. Immunology, 111, 173-178.
73. Kadowaki, N., Ho, S., Antonenko, S. et al. (2001) Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med., 194, 863-869.
74. Flacher, V., Bouschbacher, M., Verronese, E. et al. (2006) Langerhans cells express a specific TLR profile and differently respond to viruses and gram-positive bacteria. J. Immunol., 177, 7959-7967.
75. Akira, S. and Takeda, K. (2004) Toll-like receptor signaling. Nat. Rev. Immunol., 4, 499-511.
76. Akira, S., Yamamoto, M. and Takeda, K. (2003) Role of adapters in Toll-like receptor signaling . Biochem. Soc. Trans., 31, 637-642.
77. Honda, K., Yanai, H., Negishi, H. et al. (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature, 434, 772-777.
78. Chamaillard, M., Hashimoto, M., Horie, Y. et al. (2003) An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol., 4, 702-707.
79. Girardin, S.E., Boneca, I.G., Viala, J. et al. (2003) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem., 278, 8869-8872.
80. Napolitani, G., Rinaldi, A., Bertoni, F. et al. (2005) Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol., 6, 769-776.
81. Fritz, J.H., Girardin, S.E., Fitting, C. et al. (2005) Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1-and NOD2-activating agonists. Eur. J. Immunol., 35, 2459-2470
82. van Heel, D.A., Ghosh, S., Hunt, K.A. et al. (2005) Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut, 54, 1553-1557.
83. Franchi, L. and Nunez, G. (2008) The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1 β secretion but dispensable for adjuvant activity. Eur. J. Immunol., 38, 2085-2089.
84. Li, H., Willingham, S.B., Ting, J.P. and Re, F. (2008) Cutting edge: inflammasome activation by alum and alum's adjuvant effects are mediated by NLRP3. J. Immunol., 181, 17-21.
85. Dostert, C., Petrilli, V., Van Bruggen, R. et al. (2008) Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science, 320, 674-677.
86. Baruah, P., Dumitriu, I.E., Peri, G. et al. (2006) The tissue pentraxin PTX3 limitsC1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J. Leukoc. Biol., 80, 87-95.
87. Waggoner, S.N., Cruise, M.W., Kassel, R. and Hahn, Y.S. (2005) gC1q receptor ligation selectively down-regulatehuman IL-12 production through activation of the phosphoinositide 3-kinase pathway. J. Immunol., 175, 4706-4714.
88. Figdor, C.G., de Vries, I.J.M., Lesterhuis, W.J. and Melief, C.J.M. (2004) Dendritic cell immunotherapy: mapping the way. Nat. Med., 10, 475-480.